AMRN Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -78.03% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -15.41% beat DBV Technologies SA's return on equity of --.

Amarin Corp PLC has a consensus price target of $1.00, signalling upside risk potential of 121.48%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 230.64%. Given that DBV Technologies SA has higher upside potential than Amarin Corp PLC, analysts believe DBV Technologies SA is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 1.381, which suggesting that the stock is 38.057% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $62.3M, which are larger than DBV Technologies SA quarterly revenues of --. Amarin Corp PLC's net income of -$48.6M is lower than DBV Technologies SA's net income of -$23M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of -78.03% compared to Amarin Corp PLC's net margin of 17.56%. Amarin Corp PLC's return on equity of -15.41% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Amarin Corp PLC has a consensus price target of $1.00, signalling upside risk potential of 121.48%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $193.22 which suggests that it could grow by 55.64%. Given that Amarin Corp PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Amarin Corp PLC is more attractive than Jazz Pharmaceuticals PLC.

Amarin Corp PLC has a beta of 1.381, which suggesting that the stock is 38.057% more volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.096%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $62.3M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Amarin Corp PLC's net income of -$48.6M is lower than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 14.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus 1.96x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of -78.03% compared to Amarin Corp PLC's net margin of -3.91%. Amarin Corp PLC's return on equity of -15.41% beat Perrigo Co PLC's return on equity of -3.76%.

Amarin Corp PLC has a consensus price target of $1.00, signalling upside risk potential of 121.48%. On the other hand Perrigo Co PLC has an analysts' consensus of $34.60 which suggests that it could grow by 23.4%. Given that Amarin Corp PLC has higher upside potential than Perrigo Co PLC, analysts believe Amarin Corp PLC is more attractive than Perrigo Co PLC.

Amarin Corp PLC has a beta of 1.381, which suggesting that the stock is 38.057% more volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.326%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 3.99% to investors and pays a quarterly dividend of $0.29 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $62.3M, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Amarin Corp PLC's net income of -$48.6M is lower than Perrigo Co PLC's net income of -$44.5M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus 0.88x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -78.03% compared to Amarin Corp PLC's net margin of -31.41%. Amarin Corp PLC's return on equity of -15.41% beat Trinity Biotech PLC's return on equity of --.

Amarin Corp PLC has a consensus price target of $1.00, signalling upside risk potential of 121.48%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2531.58%. Given that Trinity Biotech PLC has higher upside potential than Amarin Corp PLC, analysts believe Trinity Biotech PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 1.381, which suggesting that the stock is 38.057% more volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 20.986%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $62.3M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Amarin Corp PLC's net income of -$48.6M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus 0.11x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.